Who are atezolizumab + avastin + platinum-based chemotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atezolizumab-avastin-platinum-based-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

atezolizumab + avastin + platinum-based chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

atezolizumab + avastin + platinum-based chemotherapy (atezolizumab + avastin + platinum-based chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination. Area: Oncology.

phase 3 PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination PD-L1, VEGF, DNA (platinum adducts) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

atezolizumab + avastin + platinum-based chemotherapy (atezolizumab + avastin + platinum-based chemotherapy) — ARCAGY/ GINECO GROUP. This combination uses an immune checkpoint inhibitor to block PD-L1, an anti-angiogenic monoclonal antibody to inhibit VEGF-mediated tumor blood vessel formation, and platinum-based chemotherapy to directly damage tumor DNA.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
atezolizumab + avastin + platinum-based chemotherapy TARGET	atezolizumab + avastin + platinum-based chemotherapy	ARCAGY/ GINECO GROUP	phase 3	PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination	PD-L1, VEGF, DNA (platinum adducts)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination class)

ARCAGY/ GINECO GROUP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). atezolizumab + avastin + platinum-based chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/atezolizumab-avastin-platinum-based-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab